Bartalena Luigi, Smith Terry J
The School of Medicine, University of Insubria, Varese 21100, Italy.
Department of Ophthalmology and Visual Sciences and Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI 48105, USA.
J Clin Endocrinol Metab. 2025 Mar 17;110(4):922-930. doi: 10.1210/clinem/dgaf009.
Thyroid eye disease (TED) is the most consequential extrathyroidal manifestation or complication of Graves' disease (GD). Treatment of hyperthyroidism in GD complicated by TED is challenging. Antithyroid drugs (ATDs) and thyroidectomy do not change the natural course of TED, while radioactive iodine (RAI) is associated with a small but well-documented risk of TED de novo occurrence or its progression/worsening. In the presence of mild TED, any treatment for hyperthyroidism can be used, but should RAI treatment be selected, steroid prophylaxis (short course of low-dose prednisone) is strongly recommended if TED is of recent onset and/or risk factors for progression exist. In moderate to severe and active TED, ATDs are the preferred treatment, but thyroidectomy is a valid option. RAI ablation is generally avoided; it might be used when the clinical situation calls for it, but with extreme caution, if an aggressive treatment for TED with high-dose glucocorticoids (with or without orbital radiotherapy) is administered concomitantly. In moderate to severe and inactive TED, all 3 treatments for hyperthyroidism are acceptable, and steroid prophylaxis in RAI-treated patients should be given when risk factors for TED progression are identified. Management of sight-threatening TED represents the absolute priority, and hyperthyroidism should be controlled with ATDs until TED has been controlled. Search Strategies Current guidelines, original articles, clinical trials, systematic reviews, and meta-analyses up to June 2024 were searched using the following terms: "Graves' disease," "management of Graves' disease," "antithyroid drugs," "radioactive iodine," "thyroidectomy," "thyroid eye disease," "Graves' orbitopathy or ophthalmopathy."
甲状腺眼病(TED)是格雷夫斯病(GD)最严重的甲状腺外表现或并发症。GD合并TED时甲亢的治疗具有挑战性。抗甲状腺药物(ATD)和甲状腺切除术不会改变TED的自然病程,而放射性碘(RAI)与TED新发或进展/恶化的小但有充分记录的风险相关。在轻度TED的情况下,任何甲亢治疗方法均可使用,但如果选择RAI治疗,若TED为近期发病和/或存在进展风险因素,则强烈建议进行类固醇预防(短期低剂量泼尼松疗程)。在中度至重度且活动期的TED中,ATD是首选治疗方法,但甲状腺切除术也是一种有效的选择。一般避免使用RAI消融;只有在临床情况需要时才可能使用,但要极其谨慎,同时应积极给予高剂量糖皮质激素(有或无眼眶放疗)治疗TED。在中度至重度且非活动期的TED中,所有三种甲亢治疗方法均可接受,对于接受RAI治疗的患者,若确定存在TED进展的风险因素,则应给予类固醇预防。威胁视力的TED的管理是绝对优先事项,在TED得到控制之前,应使用ATD控制甲亢。检索策略 使用以下术语检索截至2024年6月的当前指南、原始文章、临床试验、系统评价和荟萃分析:“格雷夫斯病” “格雷夫斯病的管理” “抗甲状腺药物” “放射性碘” “甲状腺切除术” “甲状腺眼病” “格雷夫斯眼眶病或眼病”